Download by
Scanning QR Code
No Stock Yet
No Data
Passage Bio to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
PHILADELPHIA, June 09, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Simona King, chief fin
Passage Bio wins FDA nod to start studies for metabolic disease candidate
Clinical-stage genetic medicines company Passage Bio (NASDAQ:PASG) announced on Wednesday that the FDA cleared its Investigational New Drug (IND) application for PBML04, a gene therapy candidate targe
Passage Bio Says FDA Clears IND Application For PBML04 To Treat Metachromatic Leukodystrophy
Genetic medicines company Passage Bio, Inc. (PASG) announced Wednesday that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for PBML04, an adeno-
Passage Bio Shares Up After FDA Clears IND Application
By Michael Dabaie Passage Bio Inc. said the U.S. Food and Drug Administration cleared its investigational new-drug application for PBML04 for the treatment of metachromatic leukodystrophy. Shares we
Passage Bio Says FDA Approves Investigational New Drug Application for Metachromatic Leukodystrophy Treatment Candidate
07:58 AM EDT, 06/08/2022 (MT Newswires) -- Passage Bio (PASG) said Wednesday the US Food and Drug Administration approved its Investigational New Drug application for PBML04, which is being studied fo
Passage Bio Receives FDA Clearance Of IND Application For PBML04 For Treatment Of Metachromatic Leukodystrophy
PBML04 represents the company's fourth program to receive IND clearancePHILADELPHIA, June 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focus
Passage Bio Chief Executive Bruce Goldsmith Resigns; Edgar Cale to Become Interim CEO
07:50 AM EDT, 06/01/2022 (MT Newswires) -- Passage Bio (PASG) said Wednesday that Bruce Goldsmith will step down as chief executive officer and president of the company, effective immediately. Edgar
Passage Bio reports Edgar Cale named interim CEO as Bruce Goldsmith steps down
Passage Bio announced that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and CEO and a member of the board, effective immediatel
Passage Bio President, CEO Bruce Goldsmith Resigns
By Colin Kellaher Passage Bio Inc. on Wednesday said Bruce Goldsmith has resigned as president, chief executive and a director by mutual agreement with the board. Passage said Edgar Cale, its genera
Passage Bio Announces Leadership Transition
Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. (Chip) Cale, current general counsel and corporate secretary, appointed as
Loading...
No Stock Yet